WallStSmart

Merck & Company Inc (MRK)vsOruka Therapeutics, Inc. (ORKA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 7.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

ORKA

Avoid

25

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 8.0
Piotroski: 1/9Altman Z: 16.52
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-60.9%)

Margin of Safety

-60.9%

Fair Value

$81.38

Current Price

$132.93

$51.55 premium

UndervaluedFair: $81.38Overvalued

Intrinsic value data unavailable for ORKA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$316.14B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

ORKA2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
16.5210/10

Safe zone — low bankruptcy risk

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
36.0x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Debt/EquityHealth
1.293/10

Elevated debt levels

ORKA4 concerns · Avg: 3.8/10
Price/BookValuation
11.1x4/10

Trading at 11.1x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : ORKA

The strongest argument for ORKA centers on Debt/Equity, Altman Z-Score.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : ORKA

The primary concerns for ORKA are Price/Book, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (50/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Oruka Therapeutics, Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Oruka Therapeutics, Inc. is a biotechnology company.

Want to dig deeper into these stocks?